冠状病毒是一类广泛存在、可感染人畜并引起严重急慢性呼吸道系统疾病的病原体。3-胰凝乳蛋白酶样蛋白酶（3CL蛋白酶）是一种位于冠状病毒非结构蛋白nsp5上的半胱氨酸蛋白酶，被认为是广谱抗冠状病毒极具吸引力的靶标之一。拟肽类3CL蛋白酶抑制剂具有更高的靶向性、更广泛的抑制谱、更低的不良反应。总结了已上市的奈玛特韦、来瑞特韦、先诺特韦、阿泰特韦和处于临床试验阶段的拟肽类3CL蛋白酶抑制剂的研究进展。

Coronavirus is a type of pathogen that is widely present, can infect humans and animals, and cause serious acute and chronic respiratory system diseases. 3-Chymotrypsin like protease (3CL protease) is a cysteine protease located on the non-structural protein nsp5 of the coronavirus, and is considered one of the highly attractive targets for broad-spectrum anti coronavirus therapy. Peptide 3CL protease inhibitors have higher targeting, wider inhibition spectrum, and lower adverse reactions. This article summarizes the research progress of the marketed drugs such as nirmatrelvir, leritrelvir, simnotrelvir, atilotrelvir, and the peptide 3CL protease inhibitors currently in clinical trials.

R974

国家自然科学基金青年科学基金项目（82204207）